This Article Full Text (PDF) References Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Karussis, D. Articles by Abramsky, O. Search for Related Content PubMed Articles by Karussis, D. Articles by Abramsky, O. Social Bookmarking                   What's this?

Acute/relapsing experimental autoimmune encephalomyelitis: Induction of long lasting, antigen-specific tolerance by syngeneic bone marrow transplantation

Department of Neurology and Laboratory of Neuroimmunology, Hadassah Hebrew University Hospital, Jerusalem, Israel

Urania Vourka-Karussis

Department of Bone Marrow Transplantation and Cancer Research Laboratory, Hadassah Hebrew University Hospital, Jerusalem, Israel

Rachel Mizrachi-Koll

Department of Neurology and Laboratory of Neuroimmunology, Hadassah Hebrew University Hospital, Jerusalem, Israel

Oded Abramsky

Department of Neurology and Laboratory of Neuroimmunology, Hadassah Hebrew University Hospital, Jerusalem, Israel

Experimental autoimmune encephalomyelitis (EAE) is an inducible autoimmune disease widely used as a model of the acute/relapsing stage of multiple sclerosis. We have previously shown that treatment of EAE-mice with high doses of cyclophosphamide (CY) (350 mg kg), followed by syngeneic bone marrow transplantation (SBMT), completely abrogates the clinical paralytic signs and even prevents the appearance of new relapses in the chronic-relapsing model of the disease. In the present study we examined whether this treatment protocol induces long term tolerance and whether this tolerance is antigen-specific. EAE was induced by immunization with spinal cord homogenate (MSCH) in complete Freund's adjuvant (CFA). The treatment with CY and SBMT was performed on day 6 post immunization. Treated and untreated mice were rechallenged with MSCH, or a non-relevant antigen (OVA) in CFA at various stages after the first paralytic attack. In contrast to previous data showing that animals recovering from acute EAE are usually refractory to re-induction of the disease, repeated injections of MSCH at different sites from the initial immunization, followed by i.v. injection of inactivated Bordetella bacteria, 2, 4 and 6 months after the initial EAE-induction, caused a severe and usually lethal relapse in all the untreated, control animals. Mice treated with CY and SBMT were resistant to all rechallenges with the same encephalitogenic inoculum. Following the second rechallenge, peripheral lymph node cells were examined in vitro for their proliferative responses to myelin antigens or to OVA. Lymphocytes obtained from CY+SBMT treated mice did not proliferate in vitro in response to myelin basic protein (MBP), but proliferated against OVA, when immunized with this antigen, after SBMT. Adoptive transfer of lymphocytes from tolerant mice to naive recipients did not transfer resistance to EAE-induction. Our results indicate that high doses of CY, followed by SBMT, induce long term antigen-specific tolerance presumably by a mechanism of clonal deletion or anergy.

Key Words: tolerance • BMT • EAE • multiple sclerosis • cyclophosphamide

Multiple Sclerosis, Vol. 5, No. 1, 017-21 (1999)
DOI: 10.1177/135245859900500104


CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this?